Ocular Therapeutix
OCUL
5.57
-0.29
-4.95%
Ocular Therapeutix
US · OCUL
#2978 by market cap
Listed 1970
5.57
-0.29
-4.95%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.7 percentage points.
Ownership vs. money flow
AlignedInstitutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 95.35% +0.65pp
- Institutions
- 308 -4
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund51.19%
Hedge Fund19.13%
VC/PE Fund15.02%
Family Office/Trust5.73%
Public Company2.04%
Private Company1.36%
Individual/Insider1.24%
Insurance Company0.60%
Government Pension Fund0.26%
Other3.41%
Top holders as of 2026-09-30
FMR
15.07% · 33.16M sh
BlackRock
9.08% · 19.97M sh
Deep Track Capital, LP
8.95% · 19.69M sh
Avoro Capital Advisors LLC
5.70% · 12.54M sh
Summer Road LLC
5.66% · 12.46M sh
VR Management, LLC
4.70% · 10.35M sh
Vanguard Capital Management, LLC
4.06% · 8.94M sh
T. Rowe Price Group, Inc.
3.46% · 7.62M sh
State Street Global Advisors
2.53% · 5.58M sh
Logos Global Management, L.P.
2.41% · 5.30M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Pravin Dugel | Chairperson & CEO | 0.36% |
| Antony Mattessich | Former Chief Executive Officer | 0.18% |
| Richard Lindstrom | Independent Director | 0.11% |
| Donald Notman | Chief Operating Officer (Leave of Absence) | 0.08% |
| Jeffrey Heier | Chief Scientific Officer | 0.08% |
| Sanjay Nayak | Former Chief Strategy Officer | 0.08% |
| Peter Kaiser | Chief Development Officer | 0.06% |
| Nadia Waheed | Chief Medical Officer | 0.04% |
| William Link | -- | 0.04% |
| Steve Meyers | Chief Commercial Officer | 0.03% |
| Namrata Saroj | Chief Business Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-05 | Riad Sherif | Director | Other Acquisition | +28,000 | -- |
| 2026-11-05 | Riad Sherif | Director | Other Derivative Acquisition | +88,000 | $6.60 |
| 2026-11-04 | Namrata Saroj | Chief Business Officer | Open Market Disposition | -35,370 | $6.55 |
| 2026-10-07 | Todd Anderman | Chief Legal Officer | Open Market Disposition | -11,984 | $7.29 |
| 2026-10-01 | Jeffrey Heier | Chief Scientific Officer | Open Market Disposition | -10,869 | $7.05 |
| 2026-10-01 | Jeffrey Heier | Independent Director | Intent to Sell (Form 144) | -10,869 | $7.05 |
| 2026-10-01 | Peter Kaiser | Chief Development Officer | Open Market Disposition | -9,990 | $7.05 |
| 2026-08-30 | Donald Notman | Chief Operating Officer (Leave of Absence) | Open Market Disposition | -1,099 | $10.24 |
| 2026-08-24 | Pravin Dugel | Chairperson & CEO | Other Acquisition | +50,092 | -- |
| 2026-08-24 | Pravin Dugel | Chairperson & CEO | Other Disposition | -50,092 | -- |
| 2026-08-23 | Jeffrey Heier | Chief Scientific Officer | Open Market Disposition | -3,296 | $10.78 |
| 2026-08-23 | Peter Kaiser | Chief Development Officer | Open Market Disposition | -3,035 | $10.77 |
| 2026-08-23 | Pravin Dugel | Chairperson & CEO | Open Market Disposition | -21,649 | $10.77 |
| 2026-08-23 | Sanjay Nayak | Former Chief Strategy Officer | Open Market Disposition | -1,897 | $10.78 |
| 2026-06-15 | Pravin Dugel | Chairperson & CEO | Other Acquisition | +50,092 | -- |
| 2026-06-15 | Pravin Dugel | Chairperson & CEO | Other Disposition | -50,092 | -- |
| 2026-06-09 | William Link | -- | Other Acquisition | +14,000 | -- |
| 2026-06-09 | William Link | -- | Other Derivative Acquisition | +44,000 | $8.74 |
| 2026-06-09 | Merilee Raines | Independent Director | Other Acquisition | +14,000 | -- |
| 2026-06-09 | Merilee Raines | Independent Director | Other Derivative Acquisition | +44,000 | $8.74 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Ocular Therapeutix discussion 0 comments